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ABSTRACT
One hundred years ago, insulin was purified and administered to
people with diabetes to lower blood glucose, suppress ketogenesis
and save lives. A century later, insulin resistance (IR) lies at the heart
of the obesity-related disease pandemic. Multiple observations attest
that IR syndrome is an amalgamation of gain and loss of insulin
action, suggesting that IR is a misnomer. This misapprehension is
reinforced by shortcomings in common model systems and is
particularly pronounced for the tissue growth disorders associated
with IR. It is necessary tomove away from conceptualisation of IR as a
pure state of impaired insulin action and to appreciate that, in the long
term, insulin can harm as well as cure. The mixed state of gain
and loss of insulin action, and its relationship to perturbed insulin-
like growth factor (IGF) action, should be interrogated more fully in
models recapitulating human disease. Only then may the potential of
rebalancing insulin action, rather than simply increasing global insulin
signalling, finally be appreciated.
Introduction
A century ago, insulin was purified from canine pancreata and
administered to people with diabetes mellitus. Until then, diabetes
was often a rapidly fatal, wasting illness, commonly of childhood
onset. Insulin therapy immediately transformed clinical outcomes.
It led to emaciated children rapidly regaining fat and muscle, their
longevity becoming measured in decades rather than months (Bliss,
1982). The ensuing years have built on this triumph, as insulin was
first sequenced (Sanger, 1959) and its three-dimensional structure
determined (Hodgkin, 1972), before recombinant human insulin
was synthesised and rolled out in clinical practice. Insulin’s primary
structure has now been rationally manipulated to yield a portfolio of
insulin analogues with kinetics optimised for exogenous use. This
has been allied with transformative developments in real-time
glucose sensing, with invention of devices able to modulate minute-
by-minute insulin delivery, and with deployment of sophisticated
algorithms to link such glucose sensing to insulin delivery.
In the face of these extraordinary advances, it is tempting to view
the century of insulin as one of unalloyed good news. Yet here the
picture becomes more complicated. Within 10 years of the first use
of insulin, it emerged that it did not have the same glucose-lowering
effect in all patients (Himsworth, 1936; Root, 1929), and the notion
of insulin insensitivity or insulin resistance (IR) was born. Decades
later, development of radioimmunoassay confirmed that insulin
concentrations are high, not low, in many people with type 2
diabetes (Yalow and Berson, 1960a,b). The tissue receptor for
insulin, known only biochemically for many years (Kasuga et al.,
1982; Freychet et al., 1971), was fully revealed in 1985 when the
sequence of the insulin receptor (INSR) gene was reported (Ullrich
et al., 1985; Ebina et al., 1985). This confirmed the receptor to be a
transmembrane tyrosine kinase. Three years after this discovery,
people with extreme IR who had loss-of-function mutations in INSR
were described (Kadowaki et al., 1988; Yoshimasa et al., 1988).
The core anatomy of postreceptor signalling was elucidated
over the next two decades (White and Kahn, 2021; Haeusler et al.,
2018). This was, for some time, commonly characterised as
a bifurcating cascade leading to mitogenic signalling through
the RAS/RAF/MEK/ERK pathway and predominantly metabolic
signalling through phosphoinositide 3-kinase (PI3K). This simple
view is no longer sustainable, however. For example, somatic
mutations activating the PI3K signalling pathway are among the
most common driver mutations in cancer and other growth disorders
(Madsen et al., 2018), and co-operation between RAS and PI3K
signalling is well documented (Castellano and Downward, 2011).
Indeed, further signalling subpathways have been identified
downstream of INSR, and a complex array of intra- and
interpathway crosstalk and feedback has been identified (White
and Kahn, 2021; Accili et al., 1996). Further challenging notions of
the linear insulin signalling pathway, some evidence suggests that
receptor tyrosine kinases, far from being static cell surface receptors
that solely initiate signalling cascades, can themselves form
transcriptional complexes within the nucleus (Goldfine and
Smith, 1976; Hancock et al., 2019). Intracellular insulin
signalling is now best viewed as being mediated by a dynamic
network of signalling and trafficking events (Accili et al., 1996).
Concerted use over many years of global and conditional murine
knockout models has addressed the nature and consequences of IR
(Biddinger and Kahn, 2006). Although these studies have provided a
valuable framework for understanding the core principles of insulin
action in vivo, there are major differences in murine and human
development, metabolism and propensity to develop IR-related tissue
pathology. This problem is compounded by the ‘glucocentric’ focus
of much historical IR literature (McGarry, 1992), and also by
organisation of clinical care into different specialities for people with
different IR-related conditions. This means that many important
mechanistic aspects of human IR and its relationships to organ
pathology in humans remain to be understood.
IR or insulin action imbalance?
IR is usually defined by reduced ability of insulin to lower blood
glucose. Diabetes only occurs when there is failure to maintain
insulin secretion in the face of the increased demand. Many people,
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usually with obesity, are in a state of compensated IR, in which
IR is balanced by increased blood insulin concentration, or
hyperinsulinaemia. IR in type 2 diabetes is only partially
compensated, with insulin concentration high, but not high
enough to normalise blood glucose. In humans, examining the
consequences of complete insulin deficiency (untreated type 1
diabetes), or compensated IR without diabetes, may be particularly
helpful in trying to determine which IR-associated conditions are
caused by IR with high insulin concentration and which are merely
associated with it, or caused by lack of insulin action.
Absolute deficiency of insulin action causes severe
hyperglycaemia due to unrestrained liver glucose output and
impaired peripheral glucose disposal. The ‘brake’ that insulin
exerts on the breakdown of triglycerides in adipose tissue is also
released, increasing fatty acid influx to the liver, fatty acid oxidation
and synthesis of ketones, a reserve fuel for the brain normally only
required in response to prolonged fasting. When lipolysis is
completely unrestrained, liver supply of fatty acids grossly
exceeds the demand of ketogenesis, and severe fatty liver and
overproduction of triglyceride-rich lipoproteins ensues. Energy
reserves in muscle are also raided, with progressive protein
catabolism releasing amino acids for liver metabolism. The net
result of these processes is ‘starvation in the midst of plenty’, the
hallmark of untreated insulin deficiency.
In fully compensated IR, no clinical or biochemical dysregulation
beyond increased size and activity of the pancreatic islets that
synthesise insulin would be expected. However, this is not what
is observed. The ‘common’ IR seen routinely in clinic, usually
with obesity, is closely associated with metabolic dysregulation
including fatty liver and increased blood lipid concentrations
(dyslipidaemia) amongst a constellation of biochemical
abnormalities.
Strikingly, many other abnormalities seen in compensated IR
feature increased tissue growth (Reaven, 2005): Acanthosis
nigricans (AN) is common in IR (Hermanns-Le et al., 2004),
and denotes a brown, velvety skin appearance in flexures such as
around the neck and under the arms. Microscopically, AN features
benign hyperproliferations of cells at several levels of the skin
(Torley et al., 2002). AN severity correlates with the severity of IR,
and AN fades when beta-cell decompensation occurs, leading to a
decrease in insulin concentration and, ultimately, diabetes. This
suggests that AN is driven by high concentrations of insulin.
Although sometimes a distressing manifestation of IR, AN is not
a major cause of morbidity. However, the skin is not the only
tissue in which hyperplasia and overgrowth are seen in response
to IR.
In severe IR, pseudoacromegaly (Flier et al., 1993) is frequently
seen, although the precise prevalence is not documented. This
denotes a pattern of soft-tissue overgrowth that mimics acromegaly,
a condition caused by excess growth hormone secretion in adults
(Flier et al., 1993; Dib et al., 1998). Far more common is polycystic
ovary syndrome (PCOS), which affects up to 10% of women and is
associated with IR in 50-70% of cases (Goodarzi et al., 2011).
PCOS is a major cause of subfertility (Goodarzi et al., 2011) and
features increased ovarian volume and histological abnormalities,
including hyperplasia of thecal cells and dyscoordinated follicular
maturation (Jonard et al., 2007). Observations of people with single-
gene causes of IR, or reversible severe IR due to INSR-blocking
autoantibodies, establish that primary IR is sufficient to induce
changes indistinguishable from PCOS, as long as secretion of
gonadotrophin hormones from the pituitary gland is intact (Huang-
Doran et al., 2021).
In the longer term, IR has been associated with increased cancer
risk, and hyperinsulinaemia is one of the factors suggested to
mediate the link between obesity and cancer (Pollack, 2007;
Gallagher and LeRoith, 2020). In the case of oestrogen-dependent
cancers, this may be explained through ovarian actions of insulin,
which increase the duration of unopposed oestrogen action on
tissues such as breast and endometrium (Nead et al., 2015).
However, direct effects of high levels of insulin to promote cell
growth and division are also likely to play a role. In the most severe
forms of childhood IR caused by loss of INSR function, severe
hyperplasia and overgrowth of the colon, ovaries and other organs,
and hypertrophic cardiomyopathy is seen (Semple et al., 2011).
Recently, there has also been increased focus on the notion that
increased blood insulin concentrations may blunt the anticancer
efficacy of inhibitors of growth factor signalling that also raise blood
glucose (Hopkins et al., 2020).
What explains the apparent disconnect between compensation for
IR with respect to blood glucose, and such a wide range of
metabolic and tissue growth abnormalities? It is likely due to false
assumptions commonly made about the negative feedback control
of insulin action. Correction to ‘normality’ would require all of
insulin’s actions on different tissues to feature similar dose
responses, and that they be subject to the same degree of negative
feedback control as each other. Were this to be untrue, then
correcting blood glucose with higher blood insulin concentration
would exert potentially harmful effects on any ‘bystander’ tissues
that remain relatively insulin responsive. This notion that
compensatory hyperinsulinaemia may have adverse consequences
on cardiometabolic outcomes, and that normalisation of plasma
glucose may be achieved only at a significant cost, was first
articulated by Gerald Reaven more than 30 years ago (Reaven,
1991).
“Correcting blood glucose with higher
blood insulin concentration would exert
potentially harmful effects on any
‘bystander’ tissues that remain relatively
insulin responsive.”
Chickens, eggs and human models
The initiating defect in common IR is unclear, and discriminating
the cause and effect in the interconnected web of IR associations is
extremely challenging. Often, causation is inferred from the
temporal sequence in which abnormalities appear. However,
human genetic variation offers one approach to test causation
more formally, if genetic variants can be identified that cause only
one element of a syndrome directly. Informative genetic variants
may be single variants with large effects on one gene, such as rare
loss-of-function mutations in INSR, or may be groups of more
common variants with much smaller effect sizes individually, as
identified in population-wide studies of IR (Scott et al., 2014;
Yaghootkar et al., 2014). For current purposes, severe genetic
defects that solely affect proximal insulin signalling, such as INSR
defects, or selectively affect adipose tissue development or
maintenance, a state known as lipodystrophy, are of particular
value (Semple et al., 2011).
If a component of the ‘IR syndrome’ is caused solely by deficient
insulin action, then it should be seen in undertreated type 1 diabetes.
If it is caused by the compensatory hyperinsulinaemia that
accompanies IR, then it will be exaggerated in people with severe
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IR due to INSR defects, as long as it depends on insulin signalling
via a non INSR-dependent pathway. Conversely, if the IR syndrome
component is reliant on INSR signalling, it will be attenuated. If a
component of the IR syndrome is caused instead by adipose tissue
dysfunction per se, it should be seen in lipodystrophy whether or not
IR is present. Finally, if it requires IR as well as adipose dysfunction,
then it will be seen in lipodystrophy with secondary IR but not in
primary IR that is caused by signalling defects.
Viewing obesity-related diabetes with IR and its associated
abnormalities through this prism reveals three distinct drivers of
abnormalities associated with common IR (Fig. 1). One group of
abnormalities, all seen in untreated type 1 diabetes, such as
hyperglycaemia and occasionally ketoacidosis, can be attributed to
loss of insulin action. Another group features increased tissue and
cellular growth in the form of AN, PCOS, pseudoacromegaly,
cardiac hypertrophy and some cancers, and is attributable to primary
IR with compensatory hyperinsulinaemia. In this group, many, and
possibly all, of these problems disappear when beta cells fail, further
implicating hyperinsulinaemia in their causation. The final group,
which may broadly be categorised as ‘lipotoxic’, requires failure of
adipose tissue homeostatic functions as well as IR (Fig. 1). Of note,
fatty liver and dyslipidaemia are most extreme in this lipotoxic
subset of IR features, but may also be caused by the most severe
degrees of insulin deficiency. In this case, they are due to
unrestrained adipose tissue lipolysis and massively increased
delivery of free fatty acid to the liver. The protection from fatty
liver seen in humans with severe IR due to INSR defects suggest that
this, too, may be regarded as a consequence of excess insulin action
in some circumstances (Semple et al., 2009), a contention supported
by extensive evidence in mice (Brown and Goldstein, 2008).
It can thus be concluded that the wide range of clinical
abnormalities seen in people with obesity-related type 2 diabetes
with IR cannot all be attributed to loss of insulin action. Instead, they
are a mixture of consequences of inadequate insulin action,
excessive insulin action and adipose failure.
“Clinical abnormalities seen in people
with obesity-related type 2 diabetes […]
are a mixture of consequences of
inadequate insulin action, excessive
insulin action and adipose failure.”
How does a compensatory increase in insulin cause
disease?
The question of how increased blood insulin concentration causes
tissue pathology in the context of IR then arises, as concomitantly
increased and attenuated insulin action seems paradoxical. The
concept of cell-autonomous ‘selective’ IR has been put forward as
the simplest possible explanation for this, first in the context of
the putative role of IR in promoting hypertension, endothelial
dysfunction and vascular complications of diabetes. This was based
on documentation of differential degrees of IR in different arms of the
insulin signalling network in endothelial cells. Specifically, blood
pressure-lowering, vasodilatory PI3K signalling was shown to be
attenuated in IR, while blood pressure-increasing, vasoconstrictor
RAS/ERK/MAPK signalling was enhanced (Potenza et al., 2005;
Zeng and Quon, 1996; Hancock et al., 2019). This cell-autonomous
explanation has also been widely discussed in the context of IR-
associated metabolic abnormalities, and in particular the regulation
of liver glucose and lipid metabolism by insulin in IR. According to
this cell-autonomous interpretation of selective IR (Brown and
Goldstein, 2008), insulin concentrations are set largely by its blood
glucose-lowering ability, given the tight feedback that glucose
exerts on pancreatic insulin secretion. Attenuation of insulin’s
glucose-lowering action first increases blood glucose and then
insulin secretion until the glucose concentration is restored to the
baseline level, at the expense of a higher blood insulin
concentration. If any branch of the complex insulin signalling
pathway is relatively unimpaired compared to the branch controlling
glucose metabolism, however, the higher insulin concentration
causes excessive activation of this pathway (Brown and Goldstein,
2008). This simple view can be refined by noting that it is not
necessary to invoke a signalling defect that is truly selective to one
branch of a pathway. A partial defect proximal to a branch point
within the pathway could also, in principle, cause differential
downstream effects if those branches have different dose responses


















Fig. 1. The common insulin resistance syndrome and type 2 diabetes
exhibit features of gain and loss of insulin action and adipose failure.
Features of insulin deficiency, excess insulin action and adipose failure are
indicated, drawing on observations of untreated type 1 diabetes, fully
compensated insulin resistance (IR) and lipodystrophy, respectively.
Bracketed features are rare and only seen in themost severe degrees of insulin
deficiency. Overlapping syndromes are numbered. (1) Characteristic of type 2
diabetes or lipodystrophy while insulin concentrations are still high. Some
features from all three groups can be seen. (2) Seen in the early stages of
decompensation of a proximal insulin signalling defect, e.g. due to INSR
mutation. Features of excess insulin action with hyperglycaemia are most
common; other features of insulin deficiency rarely develop due to residual
insulin production. (3) Seen in obesity- or lipodystrophy-related IR before beta-
cell decompensation. Commonly includes all features of lipotoxicity and
excess insulin action. (4) Seen in more advanced stages of beta-cell
decompensation in obesity- or lipodystrophy-related IR. Reversible features of
excess insulin action disappear progressively as beta-cell failure progresses.
PCOS, polycystic ovary syndrome.
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Some evidence for truly pathway-selective IR, and also for
differential downstream responses to a shared proximal signalling
defect, has been advanced in mice and humans; however, metabolic
focus has increasingly moved to a related but distinct interpretation
of selective IR. This is viewed at the tissue level, rather than
focusing on different insulin subpathways. In other words, insulin
action on different tissues exhibits differences in ‘dose response’
with respect to the physiologically important effect, such as
suppression of adipose triglyceride lipolysis, stimulation of
muscle glucose uptake and suppression of liver gluconeogenic
gene expression. Thus, even a fixed change in insulin signalling
across all tissues may have different effects on tissue metabolism,
and, as tissues are in constant metabolic dialogue mediated by
substrate flux, this often will have systemic consequences. Because
insulin levels are set predominantly by blood glucose concentration,
the tissue that plays the biggest role in this will determine the insulin
concentration that is sensed by other tissues. This sets the scene for
potential exposure of bystander tissues to increased insulin action.
It must also be remembered that many metabolic responses to
insulin depend on substrate supply as well as signalling pathway
activation. For example, although insulin activates liver
gluconeogenic gene expression, a greater determinant of liver
glucose output is delivery of substrates from adipose tissue, which is
also under control of insulin (Titchenell et al., 2016; Vatner et al.,
2015). Thus, the physiologically relevant action of insulin on liver
glucose production is actually exerted predominantly on adipose
tissue.
The role of selective IR in growth-related manifestations of IR has
been addressed less directly, in large part due to the relative lack of
these manifestations in mice. Some ex vivo studies of primary cells
from patients suggested that a selective defect in ‘metabolic
signalling’ via PI3K might explain excessive ovarian growth in
the context of PCOS or pseudoacromegaly (Flier et al., 1993; Dib
et al., 1998; Book and Dunaif, 1999; Corbould et al., 2006).
However, people with primary defects impairing INSR function
often have very-severe PCOS, arguing against this (Huang-Doran
et al., 2021; Huang-Doran et al., 2016). Indeed, the notion that
insulin exerts ‘metabolic’ effects via PI3K and ‘mitogenic’ effects
mostly via RAS/RAF/MEK/ERK sits uneasily with the overgrowth
caused by selective genetic activation of PI3K, and with the
demonstrated crosstalk between the pathways (Madsen et al., 2018;
Castellano and Downward, 2011). Although the assignment of
binary roles to distinct pathways may be naïve, the concept is not
wholly invalidated, and could be rehabilitated to take into account
that different patterns of signalling may yield different biological
outputs from the same pathway. In most cell signalling studies, the
acute response of a signal-starved pathway to ligand exposure is
assessed, but this fails to address kinetics of receptor
downregulation and recycling, and signal extinction, which may
in principle differ among tissues. These may become important
determinants of insulin sensitivity in the face of high insulin
concentrations in vivo.
A tale of non-identical twins: IGF and insulin
The INSR is expressed as two isoforms, generated by alternate
splicing of exon 11 (Seino and Bell, 1989). The B isoform, which
includes exon 11, is thought to elicit primarily metabolic outcomes,
while the A isoform promotes growth due to its high affinity for the
insulin homologue insulin-like growth factor (IGF)-II (Kosaki et al.,
1995). In common IR, the ratio of receptor isoform A to B is
reported to be increased in metabolic tissues (Besic et al., 2015), and
this has been suggested to underlie growth-related complications of
IR such as cancer, as has been comprehensively reviewed elsewhere
(Belfiore et al., 2017). Nevertheless, proving this is experimentally
challenging, and much supporting evidence is correlational.
Moreover, all naturally occurring INSR mutations described to
date are common to both receptor isoforms, arguing against skewed
INSR isoform function as the primary mechanism driving
overgrowth and other consequences of genetic INSR dysfunction.
In trying to disentangle metabolic and growth effects of insulin
action, and how they are perturbed in disease, it may thus be
necessary to look beyond insulin and its single canonical receptor
(INSR), and to consider signalling by IGFs further (LeRoith et al.,
2021). IGF-I is an endocrine hormone secreted by the liver, and a
paracrine growth factor secreted by many tissues, positively
regulated by growth hormone from the pituitary gland. IGF-I
circulates in a complex with binding proteins that modulate its
bioavailability. There is a high degree of crosstalk between insulin
and the growth hormone–IGF-I action at multiple levels of



















Fig. 2. Examples of endocrine and cellular crosstalk between insulin and
growth hormone/IGF-I action. (1) Insulin and IGFs exert negative feedback
on growth hormone secretion at the hypothalamus, and pituitary (2) insulin
upregulates hepatic growth hormone expression. (3) Insulin suppresses
IGFBP1. (4) High concentrations of insulin or IGF-I can cross-activate each
other’s receptors. Hybrid insulin/IGF-I receptors will also be present and
activated but are not shown here. (5) Close similarities of intracellular signalling
cascades for insulin and IGF-I raise the possibility of mutual signalling
potentiation. GH, growth hormone; GHRH, growth hormone-releasing
hormone; IGF, insulin-like growth factor; IGFBP, IGF-binding protein; IGF-IR,
insulin-like growth factor receptor; Ins, Insulin; INSR, insulin receptor; IRS,
insulin-responsive gene.
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receptor homologous to the INSR, the insulin-like growth factor
receptor (IGF-IR), and this can be stimulated by pathologically high
insulin concentrations. Furthermore, the INSR and IGF-IR can
heterodimerise to form so-called hybrid receptors, the existence
of which is well established, but which have distinct
(patho)physiological roles that are not fully elucidated (Siddle
et al., 1994; Siddle, 2012). IGF-II, mentioned above, also circulates
at high concentrations throughout life in humans, although much of
it is sequestered in a ternary complex (Holly et al., 2019).
“In trying to disentangle metabolic and
growth effects of insulin action, and how
they are perturbed in disease, it may thus
be necessary to look beyond insulin and
its single canonical receptor (INSR).”
Decades of research have defined distinct actions of insulin and
IGF-I in vivo, but attempts over many years to relate this to
differences in signalling architecture have instead established that
the signalling networks activated by the receptors are closely
similar. Application of modern tools has suggested there are some
quantitative differences in activation of particular elements of the
network (Cai et al., 2017; Nagao et al., 2021; Liu et al., 2012),
although many studies have used unphysiologically high ligand
concentrations, sometimes orders of magnitude above interstitial
concentrations. Collective findings, to date, suggest that ligand
availability, tissue receptor expression profiles, expression of
intracellular signalling components and, perhaps, distinct
signalling dynamics may underpin the different biological roles of
the receptors.
Given the limitations of reported mouse models discussed below,
human genetic observations currently provide the best in vivo
evidence for the interaction of insulin and IGF signalling in IR-
related pathology. For example, infants with complete or near-
complete loss of INSR function show striking soft-tissue
overgrowth, including skin, ovaries, heart, colon, kidneys and
other organs (Semple et al., 2011; Jospe et al., 1996), and this
cannot be attributed to high levels of insulin signalling through its
own receptor. In some cases of genetic INSR defects, derangement
of IGF signalling has been directly demonstrated (Hojlund et al.,
2012; Fowlkes et al., 2007). Conversely, various primary disorders
of IGF production or action are reported to perturb insulin
sensitivity (e.g. Gannage-Yared et al., 2013; Mohn et al., 2011;
Murphy et al., 2012; Douillard et al., 2020; Domené et al., 2011),
while IGF-I is frequently used as therapy for patients with extreme
recessive IR due to INSR mutations (McDonald et al., 2007).
Abundant human genetic and biochemical evidence thus argues
that dysregulation of the complex interplay between insulin and IGF
signalling plays an important role in pathogenesis of several long-
term complications of IR, particularly relating to excess tissue
growth. Further long-term study of the reciprocal growth and
metabolic complications in human monogenic disorders may yield
further insight into the potential risks and benefits of strategies
aimed at dual modulation of insulin/IGF-I signalling in IR.
Shortcomings of current models
Mouse models of acquired and genetic IR are valuable tools for
mechanistic dissection of human disease. However, there are many
important quantitative differences between mice and humans in
trajectories and regulation of development and growth, and in
configuration and hormonal regulation of metabolism. Where like-
for-like comparisons are possible between human monogenic
disorders and mouse models, similarities do not always appear.
Unlike humans with complete loss of INSR function, who live with
growth impairment and IR but not ketoacidosis for several months,
Insr knockout mice die of ketoacidosis within hours of birth (Joshi
et al., 1996; Accili et al., 1996; Nakae et al., 2001). Human
generalised lipodystrophies are fairly well modelled by knockout
mice (Rochford, 2014), but for human inherited partial
lipodystrophy, correlation between human and mouse phenotypes
is rather poor, a problem compounded by a lack of germline knock-
in models for some of the most common human lipodystrophies.
There are also important human–murine differences pertinent to
the interplay of insulin and IGFs in disease and their end-organ
effects. For example, mice do not have high circulating
concentrations of IGF-II postnatally, whereas even adult humans
have very-large circulating reservoirs (LeRoith et al., 2021; Holly
et al., 2019). The insulin-responsive gene sex hormone-binding
globulin (SHBG) links hyperinsulinaemia and altered testosterone
concentrations in humans, with genetic studies suggesting a
bidirectional relationship between SHBG and metabolic disease
(Perry et al., 2010; Semple et al., 2008), yet no orthologue circulates
in mouse plasma (Holly and Perks, 2012). Even in mouse models
that do exhibit severe IR, no robust phenotype corresponding to
human PCOS has been described (Huang-Doran and Franks, 2016).
With the exception of a single report implicating ectopic activation
of cardiac IGF signalling in a murine genetic model of generalised
lipodystrophy (Zhou et al., 2019), other aspects of tissue overgrowth
have not been studied in mouse models, to our knowledge.
Cellular studies bypass much of the complexity inherent in an
interconnected physiological system. Nevertheless, technical
limitations constrain signalling studies. Many immortalised cell
lines have levels of IGF-IR, IGF and IGF-binding protein (IGFBP)
expression that differ from those of native cells, which complicates
studies of insulin and/or IGF action. Although the existence of
INSR/IGF-IR hybrids has been documented in many cells and
tissue types, much of what is believed about their physiological
importance is inferred from circumstantial observations in the
absence of tools that selectively perturb hybrid formation but not
receptor homodimerisation (Siddle, 2012).
In summary, the complexity of the dual insulin/IGF-I signalling
system, the multifaceted differences in its constitution between
humans and rodents, and apparent differences in the propensity of
the different species to exhibit consequences of IR, complicate
Robert Semple (left) and Gemma Brierley (right)
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efforts to model and dissect long-term IR complications in mice.
Further genetic and environmental humanisation of murine models
may be possible, but, at present, studies of human ‘genetic models’
may offer the more reliable window into common disease
mechanisms.
Future directions
Medical approaches to obesity-related IR to date have tended to
focus on diabetes, dyslipidaemia and, to a lesser extent, on other
metabolic complications such as fatty liver. Nevertheless, for many
people, consequences of IR including ovarian dysfunction and
subfertility, or soft-tissue overgrowth, either benign or malignant,
are major concerns, and current evidence implicates dysregulated
IGF action in their pathogenesis in the context of IR. We thus
suggest that a more nuanced view of IR may help the metabolic field
to address the multifaceted challenges posed by the modern obesity
pandemic. It may be time to relinquish the simple endocrine
paradigm of one hormone and one receptor and a binary tissue
response. It could be of value to consider insulin and IGF
production and action as inter-related, rather than as discrete
systems that exhibit crosstalk. It will also be increasingly necessary
to address the way in which distinct outcomes may be encoded by
different spatiotemporal patterns of signalling even by the same
receptor, and how this is perturbed in disease by alteration of the
dual insulin/IGF system. Finally, the concept of ‘selective IR’
should be solidified and interpreted at an organismal as well as
cellular level. It may then be possible to develop therapeutic
strategies that rationally rebalance insulin signalling through
selective modulation of both insulin and IGF signalling, rather
than simply increasing global insulin action.
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